US pharmacy groups made billions from ‘critical drug’ price hikes

A US government report has found that three of the country’s largest pharmacy benefit managers (PBMs) “hiked costs” of “lifesaving drugs” including cancer and HIV treatments by “thousands of percent” between 2017 and 2022.